Jeff Zygouras
Directeur Financier/CFO chez NEUPATH HEALTH INC.
Fortune : 4 972 $ au 30/04/2024
Profil
Jeff Zygouras is currently the Chief Financial Officer & Secretary at NeuPath Health, Inc. He previously worked as a Finance Manager at Nuvo Pharmaceuticals, Inc. from 2018 to 2019 and as a Manager-Financial Planning & Analysis at Crescita Therapeutics, Inc. from 2016 to 2017.
Mr. Zygouras also has experience as a Member at Ernst & Young, Inc. He holds a graduate degree from the University of Toronto.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NEUPATH HEALTH INC.
0,07% | 23/11/2023 | 40 425 ( 0,07% ) | 4 972 $ | 30/04/2024 |
Postes actifs de Jeff Zygouras
| Sociétés | Poste | Début |
|---|---|---|
| NEUPATH HEALTH INC. | Directeur Financier/CFO | 30/06/2021 |
Anciens postes connus de Jeff Zygouras
| Sociétés | Poste | Fin |
|---|---|---|
| NUVO PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/06/2019 |
| CRESCITA THERAPEUTICS INC. | Corporate Officer/Principal | 01/06/2017 |
Ernst & Young, Inc.
 Ernst & Young, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young, Inc. is a professional services firm based in Toronto, Canada. The Canadian company provides a range of services and solutions to help clients transform, grow, and operate. The private company's services include strategy consulting, analytics consulting, people advisory services, transactions and corporate finance, assurance, tax planning, and legal services. The company also offers advanced technology, audit technology, tax technology, and managed services. Ernst & Young is committed to creating long-term value for all stakeholders and building a better working world. The CEO of the company is Jad Shimaly. | Corporate Officer/Principal | - |
Formation de Jeff Zygouras
| University of Toronto | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CRESCITA THERAPEUTICS INC. | Health Technology |
| NEUPATH HEALTH INC. | Finance |
| Entreprise privées | 2 |
|---|---|
Nuvo Pharmaceuticals, Inc.
 Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
Ernst & Young, Inc.
Ernst & Young, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young, Inc. is a professional services firm based in Toronto, Canada. The Canadian company provides a range of services and solutions to help clients transform, grow, and operate. The private company's services include strategy consulting, analytics consulting, people advisory services, transactions and corporate finance, assurance, tax planning, and legal services. The company also offers advanced technology, audit technology, tax technology, and managed services. Ernst & Young is committed to creating long-term value for all stakeholders and building a better working world. The CEO of the company is Jad Shimaly. | Commercial Services |
